Get sample size updates by email

Receive educational sample size content

nQuery Sample Size Software Logo Q svg

CLASSICAL

Solutions for Frequentist and Fixed-term trials
nQuery Sample Size Software Logo Q svg

BAYESIAN

Sample size using Bayesian analysis
nQuery Sample Size Software Logo Q svg

ADAPTIVE

Sample size for sophisticated Adaptive clinical trials

Get sample size updates by email

Receive great industry news once a week in your inbox

MENU
Try Now
Quote

Adaptive Design - Your Strategy for Successful Oncology Trials

April 25, 2019

To make clinical trials faster, less costly and more successful, Biopharmaceutical companies are moving from fixed to flexible study designs.

Oncology - The area with lowest likelihood of approval (LOA)

A recent report, the largest ever study of clinical development success rates, analyzed 9,985 clinical and regulatory phase transitions, across 1,103 companies and concluded that of the 14 major disease areas Oncology had the lowest likelihood of approval (LOA) with just 5.1%.

Now is the time to move from fixed to flexible trial designs

New adaptive methodologies are far more flexible than traditional designs as they allow trialists to monitor the flow of information and adjust the trial without undermining the integrity and validity of the trial.

It is said that the negative impact of high uncertainty at design stage for a confirmatory trial can be mitigated by an sample size re-estimation design.

Claim Your nQuery Pre Order Discount - CTA

Sample Size Re-Estimation for Oncology Trials

A sample size re-estimation (SSR) design is a flexible, adaptive design with the primary purpose of allowing sample size of a study to be reassessed in the mid-course of the study to ensure adequate power. Statistical analysis plans for adaptive trials should cover interim analyses to optimise efficiency with the final analyses and to draw final conclusions about the observed treatment differences.

An interim sample size reassessment aims to ensure sufficient power, adaptation of the allocation ratio to ensure more patients receive the superior treatment, dropping of inferior treatments, addition of new treatment arms to save time and resources, population “enrichment” to narrow scope of the clinical trial, or transition directly from one trial phase to another.
Source BMJ: Key design considerations for adaptive clinical trials: a primer for clinicians 

Adaptive Designs - New nQuery Release May 2019 - Email 2

What are the advantages of Sample Size Re-estimation?

  • Earlier Decisions
    You inherit the Group Sequential Design which allows the researcher to stop early for efficacy or futility. This allows the ability to adjust the trial to the reality of what the effect size is telling you will happen in the trial.

  • Reduced Potential Cost
    By having the ability to stop a trial early, you inherit the reduced costs that come with this, such as not investing money in a futile trial.

  • Higher Potential Success
    In an unblinded sample size re-estimation you have a wider range of effect sizes. In contrast to the traditional case you are now given the ability to increase the sample size for those relevant effect sizes that are lower than you initially planned for.

  • Greater Generalizability
    There’s a wider range of potential effects and this optionality might give you the ability in more complex unblinded sample size re-estimation to test additional treatments.

  • Stakeholder Buy-in
    Optionality can make up-front investment lower, which will appeal to stakeholders. There is also a better chance of success valuable to subjects.

How to increase the success of Oncology clinical trials 

A recent paper featured in Applied Clinical Trials recommends the following three steps for advancing oncology drug development:

  1. Selecting the best drug candidates
  2. Identifying and eliminating failures as early as possible
  3. Designing trials to identify the right dose, for the right disease, in the right patients as early as possible.

It is accepted that a very low number of drugs in development will be successful in demonstrating efficacy - so earlier information and better-focused evaluation are critical to improving success rates. This is where sample size re-estimation can help.

Unblinded Sample Size Re-estimation
with Interim Monitoring for Two Survival Curves 

- New nQuery Adaptive Function - Arriving May 2019 -

Led by customer demand and the need to overcome the difficulties oncology trials face, the May 2019 release of nQuery Advanced (version 8.4) will include a new section dedicated to unblinded sample size re-estimation with interim monitoring for survival analysis.

Unblinded Sample Size Re-estimation with Interim Monitoring for Two Survival Curves

So what does this mean for Biostatisticans? With this addition to nQuery, Biostatisticians can easily conduct sample size re-estimation for survival analysis, using a nQuery - the highly trusted and validated sample size platform. Using the familiar and easy to use spreadsheet interface, researchers can now quickly improve their research capabilities. 

Claim Your nQuery Pre Order Discount - CTAFrom mid May 2019, nQuery customers on the Pro Package can simply update their software to unlock this new function.

If you are not on the Pro Package of nQuery, there are great pre release discounts.

You must register your interest before the launch date, so for the greatest savings submit your details now.

Subscribe by Email

No Comments Yet

Let us know what you think